Pacira BioSciences begins patient dosing in phase 2 study evaluating safety and efficacy of PCRX-201 to treat osteoarthritis of the knee: Brisbane, California Saturday, April 5, 2 ...

Pacira BioSciences PCRX announced that it has dosed the first patient in a mid-stage study of pipeline candidate PCRX-201 ...

Variant, a company dedicated to developing innovative treatments for orphan inherited eye diseases, and the Rare Ocular Diseases Center at the University of Campania Luigi Vanvitelli (UCLV) in Naples ...

BioSciences announced the first patient has been dosed in the Phase 2 ASCEND study of PCRX-201 for the treatment of ...

Because chemogenetic control relies on DREADD expression levels, understanding and quantifying the temporal dynamics of their expression is crucial for planning long-term experiments in monkeys. In ...

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...

DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...

Administered via intravitreal injection, Synthopsin-MCO-010 possesses a promoter to specifically target ON-bipolar cells.

MeiraGTx's innovative gene therapies for ocular diseases & more are backed by strong clinical data and funding. Click here to find out why MGTX stock is a Buy.

Studies conducted in human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) compared various cassette configurations and informed the final design of TN-201, which incorporates a ...

Transgenic animals continue to play an essential role in many aspects of zebrafish research, including the development of disease models. The most widely used system for zebrafish transgenesis is the ...

过去三十年，基因治疗始终被"快递车太小"的魔咒困扰。即便最先进的工程化AAV，也只能运送相当于一本薄册子的基因片段，而治疗遗传性失明、渐冻症等疾病所需的"工具书"常常超重。研究人员尝试过各种"扩容方案"，从压缩基因序列到拆分工具组件，但就像给火箭装自 ...